If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
The Biomarker Deals and Alliances of 2013 report provides comprehensive
understanding and unprecedented access to the partnering deals and agreements
entered into by the worlds leading healthcare companies during 2013.
Using these reports, dealmakers will effectively and efficiently gain insight
into the partnering activities of the past year. The report series allows you to
view all the partnering and alliances deals announced worldwide.
The initial chapters of this report provide an orientation of 2013s dealmaking
and business activities.
Chapter 1 provides an overview of the trends in dealmaking during 2013 covering
trends by deal type, stage of development, technology type and therapeutic
Chapter 2 provides a review of the leading deals during 2013. Deals are listed
by headline value, signed by bigpharma and bigbiotech, and most active bigpharma.
Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of 2013 deals, as well
as contract documents available in the public domain. Each deal title links via
Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all partnering deals announced
The chapter is organized by company A-Z, stage of development at signing, deal
type (collaborative R&D, co-promotion, licensing etc), therapy area and
technology type. Each deal title links via Weblink to an online version of the
deal record and where available, the contract document, providing easy access to
each contract document on demand.
The report series also includes numerous tables and figures that illustrate the
trends and activities in bigpharma partnering and dealmaking during 2013.
In conclusion, this report provides everything a prospective dealmaker needs to
know about partnering in the research, development and commercialization of
technologies and products during 2013.
Biomarker Deals and Alliances of 2013 provides the reader with the following
In-depth understanding of recent dealmaking trends during 2013
Comprehensive access to all deals entered into by the worlds biopharma
companies during 2013
Detailed access to actual partnership deals and contracts entered into by the
leading fifty bigpharma companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for
Biomarker Deals and Alliances of 2013 is intended to provide the reader with an
in-depth understanding and access to parthering trends and structure of deals
entered into by leading companies worldwide.
Biomarker Deals and Alliances of 2013 includes:
Trends in dealmaking in the biopharma industry during 2013
Comprehensive directory of partnering deals in 2013
Links to online access to all deals and alliances
The leading partnering deals by value in 2013
Most active partnering dealmakers during 2013
In Biomarker Deals and Alliances of 2013 the partnering deals are listed by:
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record at
Current Agreements and where available, the contract document, providing easy
access to each contract document on demand.
Chapter 1 Trends in dealmaking during 2013
1.1. Bigpharma dealmaking activity
1.2. Partnering by deal type
1.3. Partnering by industry sector
1.4. Partnering by stage of development
1.5. Partnering by technology type
1.6. Partnering by therapy area
Chapter 2 Leading deals during 2013
2.2. Top deals by value during 2013
Chapter 3 Bigpharma deals during 2013
3.2. How to use bigpharma partnering deals
3.3. Bigpharma partnering company profiles for 2013
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Chapter 4 Partnering deals directory 2013
4.2. Company A-Z
4.3. By deal type
4.4. By stage of development
4.5. By technology type
4.6. By therapy area
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form Reports
List of Figures
Figure 1: Bigpharma top 50 January to December 2013
Figure 2: Bigpharma deal frequency 2013
Figure 3: Partnering by deal type during 2013
Figure 4: Partnering by industry sector during 2013
Figure 5: Partnering by stage of development during 2013
Figure 6: Partnering by technology type during 2013
Figure 7: Partnering by therapy area during 2013
Figure 8: Top deals by value during 2013